Results for tag: "Yonsa"

The Yonsa market is a subset of the prostate cancer drug market, focusing on the use of abiraterone acetate and its combination with prednisone. Yonsa is a novel oral therapy that is used to treat metastatic castration-resistant prostate cancer (mCRPC). It is a once-daily, oral medication that works by blocking the production of testosterone, which is necessary for the growth of prostate cancer cells. Yonsa is approved by the US Food and Drug Administration (FDA) and is available in the United States. Yonsa is a relatively new drug, and its use is growing rapidly. It is being used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes for patients with mCRPC. Yonsa is also being studied in clinical trials for its potential use in earlier stages of prostate cancer. Companies in the Yonsa market include Janssen Pharmaceuticals, Inc., Astellas Pharma US, Inc., and Myovant Sciences, Inc. Show Less Read more